BCL2 and cancer: In cancer, for example, cellular variation in anti-apoptotic protein levels (such as the Bcl2 concentration) as well as effective low number of molecules generated by over-expressed apoptotic inhibitors contribute to large cell-to-cell variability in apoptotic activation [10,13,14].